#United States #Class Action #Delaware #Pomerantz LLP #3D Systems

Pomerantz Law Firm Initiates Class Action Against 3D Systems Corporation

On July 2, 2025, Pomerantz LLP announced the initiation of a class action lawsuit against 3D Systems Corporation and several of its officers, as detailed in a press release. The lawsuit, which has been filed in the United States District Court for the District of Delaware, seeks to represent all individuals and entities, excluding the defendants, who acquired 3D Systems securities between August 13, 2024, and May 12, 2025. The plaintiffs aim to seek compensation for damages they incurred due to alleged violations of federal securities laws by the defendants.

The class action is docketed under case number 25-cv-00734. Those investors who purchased 3D Systems’ stocks during the specified class period are invited to apply to the court to be appointed as the Lead Plaintiff for the affected group. Details about filing and the complaint can be accessed through the Pomerantz website.

3D Systems is known for providing innovative 3D printing and digital manufacturing solutions globally, encompassing regions such as North America, South America, Europe, and the Asia Pacific. The company operates through two significant segments; Healthcare Solutions and Industrial Solutions, with its Healthcare segment covering a range of applications including dental and medical devices.

At the heart of the lawsuit is the claim that 3D Systems' executives made materially false and misleading statements regarding the company's financial condition and operational status. They allegedly downplayed the detrimental effects of reduced consumer spending on the company, while simultaneously overstating its financial resilience. Specifically, it is claimed that revised milestones in its Regenerative Medicine Program would negatively affect the company's revenue outlook.

In March 2025, 3D Systems released disappointing financial results for Q4 2024, reporting a non-GAAP earnings-per-share of -$0.19, which fell short of consensus estimates by $0.08. The report also revealed a year-over-year revenue decline of 3.4%, marking a troubling performance attributed largely to lower hardware system sales influenced by macroeconomic factors. As a result of these disclosures, the company’s stock price plummeted 20.96% to just $2.15.

Concerning its first quarter in 2025, the financial report indicated net losses of $37 million and revenues declining by 8% year-over-year, further straining investor confidence and resulting in additional stock price depreciation. Market analysts have raised concerns about 3D Systems' ability to achieve profitability, highlighting sustained declines in revenue and dampened investor interest in the 3D printing sector.

A significant component of the lawsuit revolves around the Regenerative Medicine Program, which includes a collaboration with United Therapeutics Corporation aimed at advancing 3D printing technology for human organ transplants, notably lung transplants. Any updates affecting the timeline for achieving key developmental milestones in this partnership could critically impact revenue projections and the overall financial viability of 3D Systems.

Pomerantz LLP has established itself as a leading firm in corporate securities class action litigation, with a long history of fighting for shareholder rights and recovering billions in damages on their behalf. Since its founding over 85 years ago, the firm has upheld the legacy of advocating against corporate misconduct and securities fraud.

Investors affected by the alleged misstatements and omissions during this class period are encouraged to reach out to Pomerantz for potential representation as they seek financial redress for their losses. The firm is committed to ensuring that shareholders are informed and protected in the complex world of securities litigation.